Abstract:Background: Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis. Methods: In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score >= 70 were treated with flexible-dose pali-ER tablets (3-12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of >= 8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety. Results: Overall, 283 of 294 patients (96%) achieved a >= 8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a >= 30% reduction in PANSS total score; 266/306 patients (87%) achieved a <= 3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score >= 71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each). Conclusion: An 8-week, flexible-dose (3-12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and was generally tolerable.

Association Between Symptom Control and Functional Improvement in Patients with Acute Schizophrenia: A Post Hoc Analysis of an Open-Label, Single-Arm, Multi-Center Study of Paliperidone-Extended Release Formulation.

Improvement in Social and Cognitive Functioning Associated with Paliperidone Extended-Release Treatment in Patients with Schizophrenia: a 24-Week, Single Arm, Open-Label Study

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia A Randomized, Double-Blind, Multicenter Study

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Clinical study on the efficacy of paliperidone extended-release tablets in the treatment of schizophrenia outpatients and its effect on social function

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis.

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Psychotic Symptoms and Attitudes Toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up

Treatment Satisfaction with Paliperidone Extended-Release Tablets: Open-Label Study in Schizophrenia Patients Dissatisfied with Previous Antipsychotic Medication

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia

Long-term Efficacy and Safety of Paliperidone Palmitate Once-Monthly in Chinese Patients with Recent-Onset Schizophrenia

Analysis of Relevant Factors Affecting the Treatment of the Negative and Positive Symptoms in Schizophrenics.

Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia

Effects of drug attitudes on treatment compliance and psychiatric symptoms of schizophrenia: an one year follow-up study

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study.

Effectiveness of Amisulpride in Chinese Patients with Predominantly Negative Symptoms of Schizophrenia: a Subanalysis of the ESCAPE Study